A Phase I clinical and pharmacological study of cis-diamminedichloro(2-methylpyridine) platinum II (AMD473)

British Journal of Cancer

Volumn 88, Issue 7, 2003, Pages 1128-1134

  Beale, P ^a   Judson, I ^b   O'Donnell, A ^b   Trigo, J ^c   Rees, C ^b   Raynaud, F ^b   Turner, A ^d   Simmons, L ^b   Etterley, L ^b  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

AMD473; Clinical trial; Phase I; Platinum

Indexed keywords

AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; CISPLATIN;

ALOPECIA; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG HALF LIFE; DRUG INFUSION; FEMALE; HEAD AND NECK CARCINOMA; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALAISE; MAXIMUM TOLERATED DOSE; MELANOMA; MESOTHELIOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; SOLID TUMOR; TASTE DISORDER; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 0038707323     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600854     Document Type: Article

References (18)

1. Bonomi P, Modiano M, Cornett P, Koehler M, Schiller J (2001) Phase II trial to assess the activity of ZD0473 in patients with small cell lung cancer who have failed one prior platinum chemotherapy regimen. Proc ASCO 20: Abstract 1284
2. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16: 31-41
3. Drug Data File, CR UK, Phase I/II Committee 1997
4. Gore ME, Atkinson RJ, Dirix L, Rischin D, Beale PJ, Harnet P, Hacking D, Cure H, Coseart J, Pemberton K, Hoctin-Boes G (2002) ZD0473 phase II monotherapy trial in second line ovarian cancer. Proc ASCO 21: Abstract 881
5. Holford J, Raynaud F, Murrer BA, Grimaldi K, Hartley J, Abrams M, Kelland LR (1998a) Chemical, biochemical and pharmacological activity of the novel sterically hindered platinum co-ordination complex, cis-[amminedichloro(2-methylpyridine)] platinum (II) (AMD473). Anti-Cancer Drug Design 13: 1-18
6. Holford J, Sharp SY, Murrer BA, Abrams M, Kelland LR (1998b) In vitro circumvention of cisplatin resistance by the novel sterically hindered platinum complex AMD473. Br J Cancer 77: 366-373
7. Judson I, Kelland LR (2000) New developments and approaches in the platinum arena. Drugs 59(Suppl 4): 29-36
8. McKeage MJ, Mistry P, Ward J, Boxall FE, Loh S, O'Neill C, Ellis P, Kelland LR, Morgan SE, Murrerr B (1995) Phase I and pharmacological study of an oral platinum complex (JM216): dose dependent pharmacokinetics with single dose administration. Cancer Chemother Pharmacol 36: 451-458
9. Mistry P, Kelland LR, Abel G, Sidhar S, Harrap KR (1991) The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer 64: 215-220
10. Nishimura T, Newkirk K, Sessions R, Andrews PA, Trock BJ, Rasmussen AA, Montgomery EA, Bischoff EK, Cullen KJ (1996) Immunohistochemical staining for glutathione S-transferase predicts response to platinum-based chemotherapy in head and neck cancer. Clin Cancer Res 2: 1859-1865
11. Quiox E, Moro D, Cosaert J (2001) ZD0473 phase II monotherapy trial in first-line non-small cell lung cancer. Proc ASCO 20: Abstract 2774
12. Raynaud FI, Mistry P, Donaghue A, Poon GK, Kelland LR, Barnard CFJ, Murrer BA, Harrap KR (1996) Biotransformation of the platinum drug JM216 following oral administration to cancer patients. Cancer Chemotherapy Pharmacol 38: 155-162
13. Raynaud FI, Boxall FE, Goddard PM (1997) Cis-ammine dichloro(2-methylpyridine) platinum (II) (AMD473), a novel sterically hindered platinum complex: in vivo activity, toxicology and pharmacokinetics in mice. Clin Cancer Res 3: 2063-2074
14. Schneiderman as described in Simon R (1993) Design and conduct of clinical Trials. In Cancer: Principles and Practice of Oncology, 4th edn. de Vita Jr V, Hillman S, Rosenberg S (eds) J.B. Lippincott, Philadelphia.
15. Stevenson JP, Blair IA, Redlinger M, Sun W, Oe T, Koehler M, Roberts D, O'Dwyer P (2001) Pharmacokinetic/pharmacodynamic trial of the novel platinum compound ZD0473 administered as an intravenous infusion every 21 days. Proc ASCO 20: Abstract 450
16. Vandenberg TA, Gelmon KA, Panasci L, Crump M, Norris B, Tomiak A, Shenkier T, Lee CW, Martin LA, Matthews S, Seymour L, Douglas L (2001) A phase II Trial of ZD0473 in patients with metastatic breast cancer, A National Cancer Institute of Canada - Clinical Trials Group Study. Proc ASCO 20: Abstract 2501
17. Van Hennik MB, van der Vijgh WJ, Klein I (1987) Comparative pharmacokinetics of cisplatin and three analogues in mice and humans. Cancer Res 47: 6297-6301
18. World Health Organisation (1979) WHO Handbook for Reporting Results of Cancer Treatment, Vol. 48. p. 7 Geneva, Switzerland: WHO; Offset Publication.